Natco Pharma Q2 FY27 Results: Exports, Domestic Sales and Margins

Natco Pharma Schedules September-Quarter Earnings Review as Investors Assess Export Markets, Domestic Formulations and Profit Margins

Hyderabad, November 13, 2026: Natco Pharma Limited is scheduled to announce its financial results for the second quarter of fiscal year 2026–27 on Friday, November 13, with investors closely monitoring international formulations, domestic pharmaceutical sales and operating profitability after a sharp decline in earnings during the preceding quarter.

The company's board is scheduled to consider its unaudited financial results for the quarter and six months ended September 30, 2026. Directors will also consider declaring a second interim dividend for FY27.

Natco Pharma has scheduled an investor and analyst conference call for 4:00 p.m. IST on November 13 to discuss the results and business outlook.

The announcement follows a difficult April–June quarter, when consolidated profit after tax declined approximately 57% year-on-year to ₹206.5 crore.

Revenue from operations fell to ₹735.2 crore, primarily because of a sharp reduction in sales of lenalidomide, a generic cancer treatment that previously contributed significantly to the company's international business.

However, domestic formulations and active pharmaceutical ingredients recorded growth, indicating that some underlying businesses continued expanding despite the decline in high-value export revenue.

The September-quarter results will provide an important indication of whether Natco Pharma is successfully reducing its dependence on individual products while building more diversified sources of earnings.

Natco Pharma Confirms November 13 Earnings Announcement

Natco Pharma informed stock exchanges on October 29 that its board would meet on November 13 to consider the September-quarter financial results.

The board will also consider a second interim dividend, although any declaration remains subject to approval.

The company subsequently confirmed its earnings conference call through a November 6 exchange communication.

The call is scheduled for 4:00 p.m. IST.

Investors will assess the financial statements alongside management's commentary on export markets, domestic formulations, research and development, and capital allocation.

The announcement comes during a period of strategic changes for the company, including a proposed rights issue and plans involving its agrochemicals business.

These developments make both operating performance and balance-sheet management important considerations.

Natco Pharma Q2 FY27 Results: Key Details

Indicator	Details
Company	Natco Pharma Limited
Headquarters	Hyderabad, Telangana
Reporting period	July–September 2026
Financial year	FY2026–27
Board meeting	November 13, 2026
Earnings conference call	November 13, 2026
Conference call time	4:00 p.m. IST
Results under consideration	Unaudited quarterly and half-year financial results
Additional board agenda	Second interim dividend, if any
NSE symbol	NATCOPHARM
BSE code	524816
Key investor focus	Export revenue, domestic formulations, profitability and product pipeline

The scheduled board meeting establishes the reporting date. The September-quarter financial performance will be determined by the approved results.

Q1 FY27 Profit Declined 57% as Export Revenue Weakened

Natco Pharma entered the September quarter after reporting a substantial decline in first-quarter earnings.

For the three months ended June 30, 2026, consolidated net profit fell to ₹206.5 crore from ₹480.3 crore a year earlier.

This represented a decline of approximately 57%.

Revenue from operations decreased to ₹735.2 crore from ₹1,328.9 crore.

The decline was largely attributable to lower revenue from lenalidomide.

The company indicated that growth in its underlying business partly offset the reduction.

However, the improvement was insufficient to compensate fully for the loss of revenue from the high-value product.

The September-quarter results will show whether the company's revenue base is stabilising.

Natco Pharma Q1 FY27 Financial Performance

Financial Indicator	Q1 FY27	Q1 FY26
Consolidated revenue from operations	₹735.2 crore	₹1,328.9 crore
Consolidated profit after tax	₹206.5 crore	₹480.3 crore
Domestic formulations revenue	₹136.4 crore	₹107 crore
International formulations revenue	₹477.1 crore	₹1,120.9 crore
Active pharmaceutical ingredients revenue	₹66.7 crore	₹52.6 crore
Total expenses	₹608.8 crore	₹818.7 crore

The figures demonstrate the contrasting performance of Natco Pharma's international and domestic businesses during the June quarter.

International Formulations Remain the Biggest Earnings Variable

Natco Pharma has a substantial presence in international pharmaceutical markets.

The company develops, manufactures and markets generic medicines across multiple therapeutic categories.

Its international formulations business has historically benefited from selected high-value generic launches.

However, revenue from such products can fluctuate significantly.

Competition, patent-related market entry and changes in pricing can reduce earnings after an initial period of strong sales.

During Q1 FY27, international formulations revenue declined to ₹477.1 crore from ₹1,120.9 crore a year earlier.

The decrease was the principal reason for the company's weaker financial performance.

Investors will examine whether international sales improved during the September quarter and whether newer products are beginning to offset declining revenue from mature generics.

Lenalidomide Revenue Decline Remains a Major Concern

Lenalidomide is used in the treatment of certain blood cancers.

Natco Pharma previously benefited from selling a generic version of the medicine in international markets.

However, the product's contribution has declined substantially as market conditions changed.

Management indicated during its previous earnings discussion that lenalidomide revenue had become negligible.

This represents an important transition for the company.

High-value generic launches can generate substantial revenue for a limited period, but those earnings may not continue indefinitely.

Investors will assess how Natco Pharma plans to replace the lost contribution through other products and markets.

The September-quarter results will provide further evidence of the company's progress.

US Generic Drug Market Faces Competitive Pricing

The United States is an important market for Indian pharmaceutical exporters.

However, the US generics industry is highly competitive.

Once multiple manufacturers introduce versions of the same medicine, prices can decline.

This can reduce revenue and profit margins even when prescription volumes remain relatively stable.

Natco Pharma's international business is exposed to these dynamics.

The company must continue developing and launching products that offer commercially attractive opportunities.

Investors will examine whether new product launches are supporting revenue diversification.

Regulatory approvals, launch timing and competition will remain important factors.

Brazil Emerges as an Important International Growth Market

Brazil has become an increasingly important market within Natco Pharma's international business.

During the June quarter, management reported Brazilian revenue of approximately ₹178 crore.

The figure represented strong year-on-year growth.

The performance was supported by the company's oncology portfolio.

Expansion in Brazil provides an opportunity to diversify international revenue beyond the United States.

However, the market has its own regulatory, pricing and competitive conditions.

Natco Pharma must also manage currency exposure and distribution requirements.

Investors will assess whether the September-quarter results show continued momentum in Brazil.

A more diversified geographic revenue base could help reduce dependence on individual products and markets.

Canadian Business Adds to International Revenue

Canada is another market contributing to Natco Pharma's international operations.

Management previously indicated that Canadian sales were approximately ₹56 crore during the June quarter.

The company's performance in Canada depends on product approvals, competitive conditions and distribution arrangements.

Although the market is smaller than the United States, it provides additional opportunities for generic medicines.

Investors will examine whether sales remained stable during July–September.

Growth across multiple international markets could help strengthen Natco Pharma's underlying business.

However, the overall financial contribution will depend on product profitability and operating expenses.

Domestic Formulations Revenue Grows Despite Export Weakness

Natco Pharma's domestic formulations business delivered growth during the June quarter.

Revenue increased to ₹136.4 crore from ₹107 crore a year earlier.

This represented growth of approximately 27.5%.

The performance contrasted with the decline in international formulations.

Domestic demand was supported by the company's pharmaceutical portfolio, including oncology-related products and newer therapies.

The Indian market provides opportunities for sustained growth, although pricing and competition remain important.

Investors will assess whether domestic formulations maintained momentum during the September quarter.

The segment's contribution is particularly important as Natco Pharma seeks to diversify its revenue sources.

Semaglutide Launch Adds a New Domestic Growth Opportunity

Natco Pharma entered India's generic semaglutide market in March 2026.

The company launched semaglutide injections under the SEMANAT and SEMAFULL brands.

Semaglutide is a GLP-1 receptor agonist used in diabetes treatment, with certain formulations also used for weight management under relevant approvals.

Natco introduced multidose vial presentations and subsequently planned pen-device options.

The launch expanded its domestic portfolio into a rapidly developing therapeutic category.

However, the market has attracted significant competition.

The company's earnings contribution will depend on pricing, distribution and patient demand.

Investors will examine whether semaglutide sales increased during the September quarter.

Semaglutide Pricing Creates Margin Challenges

Natco Pharma introduced its generic semaglutide products at relatively affordable prices.

The company announced monthly vial pricing starting at ₹1,290 for selected strengths.

Lower prices can improve access for eligible patients.

However, aggressive competition can limit manufacturer profitability.

During its previous earnings discussion, management indicated that the branded semaglutide business was generating approximately ₹2 crore in monthly revenue.

The company also suggested that margins were relatively limited.

This highlights the distinction between sales growth and profitability.

Investors will examine whether higher volumes are improving the economics of the product.

The September-quarter results may provide further insight into the commercial performance of the launch.

Oncology Portfolio Remains Important to Domestic Growth

Natco Pharma has an established presence in oncology medicines.

The company develops and markets products used in the treatment of different cancers.

Oncology remains an important therapeutic area because of demand for specialised medicines and opportunities for generic competition.

However, product development can involve complex manufacturing and regulatory requirements.

Pricing and market access also influence commercial performance.

Natco Pharma's domestic oncology portfolio contributed to the underlying business during the previous quarter.

Investors will assess whether demand continued supporting growth during July–September.

The company's ability to introduce additional products will remain important to its long-term strategy.

Active Pharmaceutical Ingredients Revenue Increases

Natco Pharma's active pharmaceutical ingredients business recorded growth during Q1 FY27.

Revenue increased to ₹66.7 crore from ₹52.6 crore in the corresponding quarter a year earlier.

This represented approximately 27% growth.

APIs are the active components used in pharmaceutical formulations.

Demand depends on manufacturing activity and customer requirements.

The business can also be influenced by raw material costs and international competition.

Investors will examine whether API revenue growth continued during the September quarter.

However, the segment's profitability must be assessed separately from revenue growth.

Profit Margins Become a Critical Indicator

Natco Pharma's profitability is influenced by product mix, international pricing and manufacturing costs.

High-value generic medicines may generate significantly different margins from more competitive products.

When revenue from a profitable product declines, the overall margin can weaken.

This can occur even if sales of other medicines increase.

The sharp decline in lenalidomide revenue therefore has implications beyond the company's total sales.

Investors will examine gross margins, operating profitability and net earnings during the September quarter.

The results will show whether the underlying business is becoming more capable of supporting sustainable profits.

Revenue Diversification Could Reduce Earnings Volatility

Natco Pharma's recent performance demonstrates the risks associated with dependence on selected high-value products.

A successful generic launch can generate substantial earnings.

However, revenue may decline when competition increases or the market opportunity changes.

Diversification across products, therapeutic categories and countries can reduce this concentration.

Natco Pharma is expanding its presence in domestic formulations and selected international markets.

However, diversification requires research spending, regulatory approvals and commercial investment.

The September-quarter results will provide evidence of how quickly newer businesses are developing.

Investors will assess whether the company's revenue mix is becoming more balanced.

Adcock Ingram Investment Adds Earnings Diversification

Natco Pharma has expanded its investment in South African pharmaceutical company Adcock Ingram Holdings.

During the June quarter, Natco held approximately 35.75% of the company.

Its share of Adcock Ingram's profit was approximately ₹84.3 crore.

In July 2026, Natco acquired an additional 13.25% stake, increasing its holding to 49%.

The additional investment was valued at approximately ₹1,060 crore.

Adcock Ingram provides exposure to the South African pharmaceutical market.

The investment could contribute to Natco Pharma's earnings diversification.

However, the financial contribution depends on the associate company's performance and applicable accounting treatment.

Investors will examine the September-quarter impact of the increased stake.

South African Pharmaceutical Market Provides New Exposure

The Adcock Ingram investment expands Natco Pharma's exposure beyond its traditional export markets.

South Africa has an established pharmaceutical market serving both public and private healthcare customers.

However, its commercial conditions differ from those in India and the United States.

Currency movements, procurement arrangements and regulation can influence profitability.

Natco Pharma's increased ownership provides greater economic exposure to Adcock Ingram's performance.

Investors will assess whether the investment strengthens recurring earnings.

However, associate profit contributions should be distinguished from Natco Pharma's own operating revenue.

Natco Pharma Approves Rights Issue of Up to ₹1,300 Crore

Natco Pharma's board approved a rights issue of up to ₹1,300 crore in September 2026.

A rights issue allows eligible existing shareholders to subscribe for additional shares under specified terms.

The company established a committee to oversee the fundraising process.

The final terms, including pricing and eligibility dates, are subject to the relevant announcements.

The proposed issue is important because it may change Natco Pharma's equity capital structure.

It could also provide financial flexibility for future investment.

However, shareholders who do not participate may experience dilution, depending on the final terms.

Investors will monitor developments in the fundraising process alongside the quarterly results.

Proposed Agrochemicals Demerger Remains Under Review

Natco Pharma has been evaluating the separation of its agrochemicals business into Natco Crop Health Sciences.

The proposed restructuring is intended to provide greater operational focus to the pharmaceutical and agrochemicals businesses.

However, the company deferred the demerger filing following its decision to pursue a rights issue.

The delay was intended to accommodate potential changes to the capital structure and related arrangements.

The company may revisit the scheme after the fundraising process.

Investors will assess whether management provides an updated timeline.

The restructuring remains subject to applicable approvals and procedural requirements.

Agrochemicals Business Faces Seasonal Demand

Natco Pharma's agrochemicals operations are influenced by agricultural activity and seasonal demand.

Crop protection product sales can vary depending on rainfall, planting schedules and farmer purchasing patterns.

Management previously indicated that the business experienced a weak June quarter.

The company expected conditions to improve during subsequent quarters.

However, actual performance depends on agricultural demand and distribution activity.

Investors will examine whether the September quarter brought stronger sales.

They will also assess whether the business is progressing toward its profitability objectives.

The proposed separation of agrochemicals adds another strategic consideration.

Research and Development Remains Central to Growth

Natco Pharma's long-term business model depends on developing and commercialising pharmaceutical products.

Research and development spending supports new formulations, complex generics and regulatory submissions.

However, pharmaceutical development involves uncertainty.

Products may face technical challenges, regulatory delays or commercial competition.

Natco Pharma has previously indicated plans to pursue multiple abbreviated new drug applications each year.

These filings support potential future launches in the United States.

However, filing an application does not guarantee approval or commercial success.

Investors will monitor the company's product pipeline and development expenditure.

Regulatory Compliance Influences Export Opportunities

Pharmaceutical manufacturers must comply with regulatory requirements in the markets where they sell medicines.

For US exports, manufacturing facilities are subject to US Food and Drug Administration standards.

Regulatory inspections can influence production approvals and product availability.

Natco Pharma has disclosed inspection-related developments at its manufacturing facilities.

However, the financial impact of any regulatory matter depends on its specific outcome.

Investors will assess whether the company reports material developments affecting export operations.

Maintaining manufacturing compliance remains important for international business growth.

Currency Movements Can Affect Export Earnings

Natco Pharma earns revenue from several international markets.

Foreign currency movements can influence the rupee value of export sales.

A weaker rupee may increase reported export revenue when foreign-currency receipts are translated into Indian currency.

However, the company may also incur foreign-currency expenses.

The overall effect depends on the balance of revenue, costs and hedging arrangements.

Investors will examine whether currency movements influenced September-quarter profitability.

However, exchange-rate effects should be distinguished from underlying changes in product demand and pricing.

FY27 Guidance Will Be Closely Watched

During its previous earnings discussion, Natco Pharma management indicated full-year profit after tax guidance of approximately ₹750 crore.

It also referred to gross sales guidance of approximately ₹3,300 crore to ₹3,400 crore.

These figures represented management expectations rather than guaranteed outcomes.

The September-quarter results will provide information about progress toward those objectives.

Investors will examine whether the company maintains or revises its outlook.

A recovery in international sales, growth in domestic formulations and contributions from associates could influence the full-year performance.

However, product pricing and competitive conditions remain important sources of uncertainty.

Capital Allocation Becomes an Important Investor Question

Natco Pharma is managing several financial priorities.

These include research and development, product launches, international expansion and strategic investments.

The increased stake in Adcock Ingram represents a substantial capital commitment.

The proposed rights issue could also influence the company's financial structure.

Investors will assess how management plans to allocate capital between organic growth and acquisitions.

They will also examine cash balances, operating cash flow and investment requirements.

Efficient capital allocation will be important to sustaining long-term shareholder returns.

Second Interim Dividend Under Consideration

Natco Pharma's board will consider declaring a second interim dividend for FY27 at its November 13 meeting.

An interim dividend is a distribution to shareholders made before the end of the financial year.

However, a dividend is not guaranteed merely because it appears on the board agenda.

The amount, record date and payment arrangements would depend on the board's decision and subsequent disclosures.

Investors will monitor the announcement alongside the financial results.

Dividend decisions may also reflect the company's cash position and capital requirements.

Indian Pharmaceutical Industry Faces Mixed Conditions

India's pharmaceutical industry serves both domestic and international markets.

The domestic market benefits from demand for medicines across chronic and acute therapeutic categories.

Export businesses are influenced by regulatory approvals, pricing and competition.

Generic drug manufacturers can experience significant earnings volatility when high-value products lose exclusivity or face new competitors.

Natco Pharma's recent performance illustrates this challenge.

However, the company also has opportunities to develop new products and expand geographically.

Investors will assess whether its underlying businesses can provide more stable earnings over time.

What Investors Will Watch in the Q2 FY27 Results

The November 13 announcement will be evaluated across several financial and operational indicators.

International formulations revenue will show whether export sales have stabilised after the decline in lenalidomide revenue.

Domestic formulations growth will indicate the performance of the company's Indian pharmaceutical portfolio.

Operating margins will provide insight into product mix and cost management.

The contribution from Adcock Ingram will also be important.

Investors will monitor the rights issue, proposed agrochemicals demerger and any dividend declaration.

Management commentary on the product pipeline and FY27 guidance may influence expectations for the remainder of the year.

Natco Pharma Shares May React to Earnings

Natco Pharma shares trade on the National Stock Exchange and Bombay Stock Exchange.

Quarterly results can influence market sentiment when financial performance differs from expectations.

A recovery in international revenue or stronger domestic growth could support investor confidence.

However, continued margin pressure may weigh on sentiment.

The market response will also depend on the company's valuation, capital allocation plans and management outlook.

Investors may pay particular attention to whether the business is becoming less dependent on individual high-value generic products.

Broader pharmaceutical sector and equity market conditions may also influence trading.

Outlook for Natco Pharma in FY27

Natco Pharma enters the second half of FY27 during a period of business transition.

The decline in lenalidomide revenue has reduced earnings from a historically important product.

However, domestic formulations, selected international markets and active pharmaceutical ingredients provide opportunities for growth.

The increased investment in Adcock Ingram adds another potential earnings contributor.

At the same time, the proposed rights issue and agrochemicals restructuring create capital allocation considerations.

The September-quarter results will provide an important update on whether the underlying pharmaceutical business is strengthening.

Management's outlook will help investors assess the prospects for the remainder of FY27.

Conclusion

Natco Pharma's November 13 earnings announcement will place international formulations, domestic pharmaceutical sales and profit margins at the centre of investor attention.

The company entered the September quarter after reporting a 57% decline in first-quarter net profit to ₹206.5 crore.

The decline was largely attributable to reduced revenue from lenalidomide, highlighting the earnings volatility associated with high-value generic medicines.

However, domestic formulations and active pharmaceutical ingredients recorded growth.

The company has also expanded its investment in Adcock Ingram and approved a proposed rights issue of up to ₹1,300 crore.

These developments reflect a broader effort to diversify earnings and strengthen the business.

Investors will now assess whether September-quarter performance demonstrates improving revenue stability, stronger margins and progress toward management's FY27 objectives.

The financial results and earnings conference call will provide the next important indicators of Natco Pharma's operating and strategic direction.